Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022175436 - INFLUENZA VIRUS DEFECTIVE INTERFERING PARTICLES FOR USE IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF CORONAVIRIDAE INFECTION

Publication Number WO/2022/175436
Publication Date 25.08.2022
International Application No. PCT/EP2022/054047
International Filing Date 18.02.2022
IPC
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
A61K 35/76 2015.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
C12N 7/04 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
04Inactivation or attenuation; Producing viral sub-units
CPC
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C12N 2760/16121
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2760ssRNA Viruses negative-sense
00011ssRNA Viruses negative-sense
16011Orthomyxoviridae
16111Influenzavirus A, i.e. influenza A virus
16121Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N 2760/16123
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2760ssRNA Viruses negative-sense
00011ssRNA Viruses negative-sense
16011Orthomyxoviridae
16111Influenzavirus A, i.e. influenza A virus
16123Virus like particles [VLP]
C12N 2760/16132
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2760ssRNA Viruses negative-sense
00011ssRNA Viruses negative-sense
16011Orthomyxoviridae
16111Influenzavirus A, i.e. influenza A virus
16132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N 2760/16133
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2760ssRNA Viruses negative-sense
00011ssRNA Viruses negative-sense
16011Orthomyxoviridae
16111Influenzavirus A, i.e. influenza A virus
16133Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Applicants
  • MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. [DE]/[DE]
  • HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH [DE]/[DE]
  • OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG [DE]/[DE]
Inventors
  • KUPKE, Sascha
  • REICHL, Udo
  • HEIN, Marc Dominique
  • BRUDER, Dunja
  • RAND, Ulfert
Agents
  • GRAMM, LINS & PARTNER PATENT- UND RECHTSANWÄLTE PARTGMBB
Priority Data
21157812.518.02.2021EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) INFLUENZA VIRUS DEFECTIVE INTERFERING PARTICLES FOR USE IN THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF CORONAVIRIDAE INFECTION
(FR) PARTICULES INTERFÉRENTES DÉFECTUEUSES DE VIRUS DE LA GRIPPE DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT PROPHYLACTIQUE OU THÉRAPEUTIQUE D'UNE INFECTION PAR CORONAVIRUS
Abstract
(EN) The present invention relates in a first aspect to the use of influenza virus defective interfering particles in the prophylactic or therapeutic treatment of coronaviridae infection. In particular, it has been recognized that defective interfering particles of influenza A have beneficial effects in the treatment of SARS coronavirus infection, in particular, SARS-CoV-2 infection. Further, the present invention relates to a pharmaceutical composition for use in treating coronaviridae infection, in particular SARS-CoV-2. In a further aspect, methods for the prophylactic or therapeutic treatments of coronaviridae based on the administration of DIFs are disclosed.
(FR) La présente invention concerne, selon un premier aspect, l'utilisation de particules interférentes défectueuses de virus de la grippe dans le traitement prophylactique ou thérapeutique d'une infection par coronavirus. En particulier, il a été reconnu que des particules interférentes défectueuses de la grippe A ont des effets bénéfiques dans le traitement d'une infection à coronavirus du SRAS, en particulier, une infection par le SARS-CoV-2. En outre, la présente invention concerne une composition pharmaceutique destinée à être utilisée dans le traitement d'une infection à coronavirus, en particulier le SARS-CoV-2. Dans un autre aspect, l'invention concerne des méthodes pour les traitements prophylactiques ou thérapeutiques de coronavirus sur la base de l'administration de DIF.
Related patent documents
Latest bibliographic data on file with the International Bureau